Conclusions
4 evidence topics · 41 sources
Summary: disease burden in MASH with F2 to F3 fibrosis
The 2023 AASLD practice guidance refers to NASH with at least stage 2 fibrosis as at-risk NASH, with a higher risk of liver-related morbidity and mortality. In 14 articles of cohort studies involving 17,301 patients with biopsy-proven NAFLD, all-cause mortality hazard ratios compared with stage 0 were 1.46 for stage 2 and 1.96 for stage 3, and liver-related mortality hazard ratios were 4.07 and 7.59. In a cohort analysis supported by Novo Nordisk Inc., incidence rates of cirrhosis were 1.24/100PM for F2 and 6.62/100PM for F3, and in a cohort of 1,260 patients with NAFLD without cirrhosis the 20-year cumulative incidence of major adverse liver outcomes was 35% for F3. A pooled analysis of 54 studies estimated the time to progress by one fibrosis stage at 13.3 years from F2 and 22.2 years from F3.
US population estimates depend on the model. An eligible-population model applied a NASH prevalence of 4.6% (range 1.3% to 14.2%) and a non-cirrhotic F2 to F3 proportion of 35%; the ICER budget impact analysis applied a prevalence of 1.4% to US adults, an average of 3.81 million eligible patients; and another model projected cases of MASH with F2 or higher fibrosis to increase from 6.7 million in 2020 to 11.7 million by 2050. A diagnosis rate of ~10% (range 3.3% to 14.3%) of the treatment-eligible population has been estimated, and NHANES survey responses indicate that 14.3% of prevalent patients with F2 to F3 NASH have received a diagnosis of liver disease. In the GAIN study, mean EQ-5D index values among US respondents were 0.80 for early (F0 to F2) and 0.67 for advanced (F3 to F4) fibrosis. The ICER model used annual health care costs of $7,063 for F0 to F2 and $8,423 for F3.
Summary: lanifibranor phase 2 efficacy and safety
The histologic evidence on lanifibranor comes from NATIVE (NCT03008070), a 24-week phase 2b trial in which 247 participants with noncirrhotic, highly active NASH were randomized to lanifibranor 1200 mg (83), lanifibranor 800 mg (83), or placebo (81); 188 participants (76%) had F2 or F3 fibrosis, and all biopsy samples were read by one pathologist. The primary end point (a decrease of at least 2 points in the SAF-A score without worsening of fibrosis) is reported with three analyses:
- Full analysis population with multiple imputation (the published primary analysis): 55% with 1200 mg, 48% with 800 mg, and 33% with placebo (P=0.007 for 1200 mg and P=0.07 for 800 mg).
- ITT population in the company topline release: 49% (P=0.004), 41% (P=0.061), and 27%.
- Registry results counting missing data as nonresponse: 41 of 83, 34 of 83, and 22 of 81 responders. The protocol's primary rule counted missing data as nonresponse, and week 24 biopsies were missing for 34 participants.
With multiple imputation, resolution of NASH without worsening of fibrosis occurred in 49%, 39%, and 22%, and improvement in fibrosis of at least 1 stage without worsening of NASH in 48%, 34%, and 29%. The composite of NASH resolution and fibrosis improvement, which is the NATiV3 primary composite endpoint, occurred in 35%, 25%, and 9% with multiple imputation and in 31%, 21%, and 7% in the ITT topline analysis. No multiplicity adjustments were defined for secondary and exploratory end points. An analysis of 29 randomized controlled trials reported a risk ratio of 1.93 (CrI 1.30 to 3.02) for lanifibranor versus placebo for MASH resolution without worsening fibrosis, based mostly on indirect comparisons. The primary endpoint of LEGEND (39 participants with type 2 diabetes treated for 24 weeks) was the change in HbA1c, and that of NCT03459079 (38 participants with type 2 diabetes and MASLD) was the change in intrahepatic triglyceride content.
Safety figures in NATIVE (1200 mg, 800 mg, placebo) were: serious adverse events 7 (8%), 3 (4%), and 3 (4%), with no deaths; diarrhea 10 (12%), 8 (10%), and 1 (1%); weight gain reported as an adverse event in 7 (8%), 8 (10%), and 0, with mean body weight increases of 2.7 kg (3.1%) with 1200 mg and 2.4 kg (2.6%) with 800 mg; peripheral edema in 7 (8%), 5 (6%), and 2 (2%); and anemia in 6 (7%), 1 (1%), and 0. Discontinuations for adverse events were 3 (4%), 4 (5%), and 3 (4%) in the journal report and 3, 3, and 3 in the registry participant flow. In LEGEND, relative body weight change was 3.6% with lanifibranor alone, and in NCT03459079 mean weight change was +2.7% with lanifibranor and −1.0% with placebo, with anemia in 4 of 20 (20%) and 2 of 18 (11%). In NATiV3, a treatment-related suspected unexpected serious adverse reaction of elevated liver tests with biopsy results compatible with autoimmune hepatitis led to a pause in screening, a protocol amendment excluding patients diagnosed with or predisposed to autoimmune liver or thyroid disease, and liver monitoring every 6 weeks. The manufacturer's Form 20-F states that weight gain with lanifibranor may lead patients to prefer a GLP-1 agent for the treatment of MASH.
Summary: evidence not available until NATiV3 reports, and the regulatory path
Lanifibranor “has not been approved for use by any regulatory authority”, and no price, proposed labeling, or commercial dose was identified. NATiV3 (NCT04849728) randomized adults with biopsy-proven noncirrhotic MASH and F2 or F3 fibrosis 1:1:1 to lanifibranor 800 mg or 1200 mg once daily or placebo for 72 weeks. All participants had completed the 72-week treatment period, the registry lists an actual primary completion date of 2026-09-29, and topline results were expected in the fourth quarter of 2026; no NATiV3 efficacy results were identified. Until it reports, the following remain unknown or differ by source:
- Efficacy in the F2 to F3 population at 72 weeks, and in a main cohort in which 67.0% had F3 fibrosis, 55% had type 2 diabetes, 14.0% were taking a GLP-1 receptor agonist, and 10.0% an SGLT2 inhibitor at baseline, compared with 42% type 2 diabetes and 0.0% GLP-1 receptor agonist use in NATIVE in the same slides.
- The endpoints that will support a submission: the registry and the investor and analyst day presentation name the composite of NASH resolution and fibrosis improvement as primary, and the Form 20-F financing terms name the two single histologic endpoints.
- The number analyzed: 1,009 participants in the main cohort and 410 in an exploratory cohort (company), an estimated enrollment of 1000 (registry), and approximately 950 patients for the NDA analysis (Form 20-F).
- Unblinded safety: at one Data Monitoring Committee review, the data were unblinded to the committee and remained blinded with respect to the company, and the committee recommended continuing the trial without modification of the protocol.
- Drug interactions: an amendment driven by preliminary results of drug-drug interaction study 337HVPK21014 excludes substrates of CYP2B6 and CYP2C8, and no published results of that study were identified.
If results are favorable, the company anticipates a regulatory submission in the first half of 2027 under the FDA accelerated approval pathway and is preparing for a potential U.S. launch in 2028, subject to FDA approval. The FDA has granted lanifibranor Breakthrough Therapy and Fast Track designation for the treatment of MASH. Accelerated approval, if granted, requires completion of the trial for full approval, and a separate event-driven phase 3 outcome trial in MASH with compensated cirrhosis, expected to last approximately three years, is planned. The EASL guideline states that agents receiving accelerated approval must demonstrate beneficial effects on clinical outcomes.
Summary: approved comparators and economic evidence
Resmetirom and semaglutide 2.4 mg are approved for noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3), both under accelerated approval based on improvement of MASH and fibrosis. In the resmetirom label's month 12 analysis of 888 F2 and F3 patients, with missing biopsies counted as nonresponse, resolution of steatohepatitis without worsening of fibrosis occurred in 27% (80 mg) and 36% (100 mg) versus 13% with placebo by Pathologist A, and 26% and 24% versus 9% by Pathologist B. In the semaglutide label's week 72 analysis of 800 F2 and F3 patients, with reference-based multiple imputation, resolution of steatohepatitis without worsening of fibrosis occurred in 63% versus 34%, and improvement in liver fibrosis without worsening of steatohepatitis in 37% versus 22%. No head-to-head trial of lanifibranor with either agent has been conducted, and resmetirom and semaglutide have not been studied in combination or compared. Pioglitazone and vitamin E are not FDA approved for MASH.
No price, cost-effectiveness analysis, or budget impact analysis of lanifibranor was identified. The comparators have published prices: resmetirom has a wholesale acquisition cost of $4,239.38 per 30-tablet package for each strength as of October 1, 2026, and semaglutide 2.4 mg has a list price of $1,349.02 per package, which Novo Nordisk announced will be lowered to $675, effective January 1, 2027. ICER's May 2023 assessment rated resmetirom “C++” compared with standard of care, set a health-benefit price benchmark of $39,600 to $50,100, and issued an access and affordability alert. Published US analyses report incremental cost-effectiveness ratios that vary by study: for semaglutide, $19,911 to $80,076 per QALY, and for resmetirom, $53,929 to $346,810 per QALY, with drug price the most influential parameter in one model. A Madrigal-funded budget impact analysis for a hypothetical one-million-member US private plan estimated a resmetirom net budget impact of $2.2 to $9.5 million over years 1 to 3, or $0.19 to $0.80 per member per month. Published utility weights for these health states include 0.76 (F0 to F2) and 0.73 (F3) in the ICER model, and 0.671 (MASH F2) and 0.605 (MASH F3) in another model.